dr. suresh ramalingam explores cytotoxics in lung cancer
Published 11 years ago • 153 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
1:21
dr. suresh s. ramalingam on optimizing immunotherapies in lung cancer
-
1:06
dr. suresh ramalingam on hsp90 inhibition with ganetespib in lung cancer
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
2:04
dr. ramalingam discusses the utility of tecemotide in nsclc
-
3:05
suresh ramalingam discusses side effects associated with immunotherapy in lung cancer
-
0:59
dr. suresh ramalingam reviews the galaxy-1 trial results
-
1:43
dr. ramalingam discusses the results of the phase iii revel study in nsclc
-
3:13
dr. ramalingam on side effects associated with immunotherapy in lung cancer
-
1:19
dr. ramalingam on emerging combination regimens in nsclc
-
1:10
dr. suresh ramalingam on immune checkpoint inhibitors in nsclc treatment
-
0:34
dr. ramalingam on the safety of tecemotide
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
18:42
gracecast-134_ca-101_dr. suresh ramalingam: what is a clinical trial?
-
18:07
2020 winship scientific symposium | suresh ramalingam, md
-
2:53
dr. suresh ramalingam on hsp90 inhibition with ganetespib
-
1:40
suresh ramalingam on toxicities associated with immunotherapy in different disease types
-
6:51
researcher comment: three-year data from checkmate 227 | suresh ramalingam
-
1:16
suresh ramalingam, md, offers opinion on optimal sequencing of immunotherapy in nsclc